Literature DB >> 17671654

Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo.

Kerstin Schwarzwaelder1, Steven J Howe, Manfred Schmidt, Martijn H Brugman, Annette Deichmann, Hanno Glimm, Sonja Schmidt, Claudia Prinz, Manuela Wissler, Douglas J S King, Fang Zhang, Kathryn L Parsley, Kimberly C Gilmour, Joanna Sinclair, Jinhua Bayford, Rachel Peraj, Karin Pike-Overzet, Frank J T Staal, Dick de Ridder, Christine Kinnon, Ulrich Abel, Gerard Wagemaker, H Bobby Gaspar, Adrian J Thrasher, Christof von Kalle.   

Abstract

We treated 10 children with X-linked SCID (SCID-X1) using gammaretrovirus-mediated gene transfer. Those with sufficient follow-up were found to have recovered substantial immunity in the absence of any serious adverse events up to 5 years after treatment. To determine the influence of vector integration on lymphoid reconstitution, we compared retroviral integration sites (RISs) from peripheral blood CD3(+) T lymphocytes of 5 patients taken between 9 and 30 months after transplantation with transduced CD34(+) progenitor cells derived from 1 further patient and 1 healthy donor. Integration occurred preferentially in gene regions on either side of transcription start sites, was clustered, and correlated with the expression level in CD34(+) progenitors during transduction. In contrast to those in CD34(+) cells, RISs recovered from engrafted CD3(+) T cells were significantly overrepresented within or near genes encoding proteins with kinase or transferase activity or involved in phosphorus metabolism. Although gross patterns of gene expression were unchanged in transduced cells, the divergence of RIS target frequency between transduced progenitor cells and post-thymic T lymphocytes indicates that vector integration influences cell survival, engraftment, or proliferation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17671654      PMCID: PMC1934556          DOI: 10.1172/JCI31661

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  29 in total

1.  Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking.

Authors:  Olga Kustikova; Boris Fehse; Ute Modlich; Min Yang; Jochen Düllmann; Kenji Kamino; Nils von Neuhoff; Brigitte Schlegelberger; Zhixiong Li; Christopher Baum
Journal:  Science       Date:  2005-05-20       Impact factor: 47.728

2.  Recurrent retroviral vector integration at the Mds1/Evi1 locus in nonhuman primate hematopoietic cells.

Authors:  Boris Calmels; Cole Ferguson; Mikko O Laukkanen; Rima Adler; Marion Faulhaber; Hyeoung-Joon Kim; Stephanie Sellers; Peiman Hematti; Manfred Schmidt; Christof von Kalle; Keiko Akagi; Robert E Donahue; Cynthia E Dunbar
Journal:  Blood       Date:  2005-06-02       Impact factor: 22.113

3.  Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector.

Authors:  H Bobby Gaspar; Kathryn L Parsley; Steven Howe; Doug King; Kimberly C Gilmour; Joanna Sinclair; Gaby Brouns; Manfred Schmidt; Christof Von Kalle; Torben Barington; Marianne A Jakobsen; Hans O Christensen; Abdulaziz Al Ghonaium; Harry N White; John L Smith; Roland J Levinsky; Robin R Ali; Christine Kinnon; Adrian J Thrasher
Journal:  Lancet       Date:  2004 Dec 18-31       Impact factor: 79.321

4.  Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells.

Authors:  Alessandra Recchia; Chiara Bonini; Zulma Magnani; Fabrizia Urbinati; Daniela Sartori; Sara Muraro; Enrico Tagliafico; Attilio Bondanza; Maria Teresa Lupo Stanghellini; Massimo Bernardi; Alessandra Pescarollo; Fabio Ciceri; Claudio Bordignon; Fulvio Mavilio
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-23       Impact factor: 11.205

5.  Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis.

Authors:  Ute Modlich; Olga S Kustikova; Manfred Schmidt; Cornelia Rudolph; Johann Meyer; Zhixiong Li; Kenji Kamino; Nils von Neuhoff; Brigitte Schlegelberger; Klaus Kuehlcke; Kevin D Bunting; Sonja Schmidt; Annette Deichmann; Christof von Kalle; Boris Fehse; Christopher Baum
Journal:  Blood       Date:  2005-02-15       Impact factor: 22.113

6.  Inactivation of the Moloney murine leukemia virus long terminal repeat in murine fibroblast cell lines is associated with methylation and dependent on its chromosomal position.

Authors:  R C Hoeben; A A Migchielsen; R C van der Jagt; H van Ormondt; A J van der Eb
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

7.  Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1.

Authors:  Marion G Ott; Manfred Schmidt; Kerstin Schwarzwaelder; Stefan Stein; Ulrich Siler; Ulrike Koehl; Hanno Glimm; Klaus Kühlcke; Andrea Schilz; Hana Kunkel; Sonja Naundorf; Andrea Brinkmann; Annette Deichmann; Marlene Fischer; Claudia Ball; Ingo Pilz; Cynthia Dunbar; Yang Du; Nancy A Jenkins; Neal G Copeland; Ursula Lüthi; Moustapha Hassan; Adrian J Thrasher; Dieter Hoelzer; Christof von Kalle; Reinhard Seger; Manuel Grez
Journal:  Nat Med       Date:  2006-04-02       Impact factor: 53.440

8.  Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes.

Authors:  T D Palmer; G J Rosman; W R Osborne; A D Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

9.  New insights on human T cell development by quantitative T cell receptor gene rearrangement studies and gene expression profiling.

Authors:  Willem A Dik; Karin Pike-Overzet; Floor Weerkamp; Dick de Ridder; Edwin F E de Haas; Miranda R M Baert; Peter van der Spek; Esther E L Koster; Marcel J T Reinders; Jacques J M van Dongen; Anton W Langerak; Frank J T Staal
Journal:  J Exp Med       Date:  2005-05-31       Impact factor: 14.307

10.  Distinct genomic integration of MLV and SIV vectors in primate hematopoietic stem and progenitor cells.

Authors:  Peiman Hematti; Bum-Kee Hong; Cole Ferguson; Rima Adler; Hideki Hanawa; Stephanie Sellers; Ingeborg E Holt; Craig E Eckfeldt; Yugal Sharma; Manfred Schmidt; Christof von Kalle; Derek A Persons; Eric M Billings; Catherine M Verfaillie; Arthur W Nienhuis; Tyra G Wolfsberg; Cynthia E Dunbar; Boris Calmels
Journal:  PLoS Biol       Date:  2004-11-23       Impact factor: 8.029

View more
  96 in total

1.  A self-inactivating lentiviral vector for SCID-X1 gene therapy that does not activate LMO2 expression in human T cells.

Authors:  Sheng Zhou; Disha Mody; Suk See DeRavin; Julia Hauer; Taihe Lu; Zhijun Ma; Salima Hacein-Bey Abina; John T Gray; Michael R Greene; Marina Cavazzana-Calvo; Harry L Malech; Brian P Sorrentino
Journal:  Blood       Date:  2010-05-10       Impact factor: 22.113

Review 2.  Hematopoietic stem cell engineering at a crossroads.

Authors:  Isabelle Rivière; Cynthia E Dunbar; Michel Sadelain
Journal:  Blood       Date:  2011-11-17       Impact factor: 22.113

3.  Integration frequency and intermolecular recombination of rAAV vectors in non-human primate skeletal muscle and liver.

Authors:  Ali Nowrouzi; Magalie Penaud-Budloo; Christine Kaeppel; Uwe Appelt; Caroline Le Guiner; Philippe Moullier; Christof von Kalle; Richard O Snyder; Manfred Schmidt
Journal:  Mol Ther       Date:  2012-03-27       Impact factor: 11.454

4.  Counting stem cells: methodological constraints.

Authors:  Leonid V Bystrykh; Evgenia Verovskaya; Erik Zwart; Mathilde Broekhuis; Gerald de Haan
Journal:  Nat Methods       Date:  2012-05-30       Impact factor: 28.547

5.  Genome-wide high-throughput integrome analyses by nrLAM-PCR and next-generation sequencing.

Authors:  Anna Paruzynski; Anne Arens; Richard Gabriel; Cynthia C Bartholomae; Simone Scholz; Wei Wang; Stephan Wolf; Hanno Glimm; Manfred Schmidt; Christof von Kalle
Journal:  Nat Protoc       Date:  2010-07-08       Impact factor: 13.491

6.  Lentiviral vector gene therapy: effective and safe?

Authors:  Derek A Persons
Journal:  Mol Ther       Date:  2010-05       Impact factor: 11.454

7.  Retroviral integration and human gene therapy.

Authors:  Frederic D Bushman
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

8.  Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy.

Authors:  Annette Deichmann; Salima Hacein-Bey-Abina; Manfred Schmidt; Alexandrine Garrigue; Martijn H Brugman; Jingqiong Hu; Hanno Glimm; Gabor Gyapay; Bernard Prum; Christopher C Fraser; Nicolas Fischer; Kerstin Schwarzwaelder; Maria-Luise Siegler; Dick de Ridder; Karin Pike-Overzet; Steven J Howe; Adrian J Thrasher; Gerard Wagemaker; Ulrich Abel; Frank J T Staal; Eric Delabesse; Jean-Luc Villeval; Bruce Aronow; Christophe Hue; Claudia Prinz; Manuela Wissler; Chuck Klanke; Jean Weissenbach; Ian Alexander; Alain Fischer; Christof von Kalle; Marina Cavazzana-Calvo
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

9.  Comprehensive genomic access to vector integration in clinical gene therapy.

Authors:  Richard Gabriel; Ralph Eckenberg; Anna Paruzynski; Cynthia C Bartholomae; Ali Nowrouzi; Anne Arens; Steven J Howe; Alessandra Recchia; Claudia Cattoglio; Wei Wang; Katrin Faber; Kerstin Schwarzwaelder; Romy Kirsten; Annette Deichmann; Claudia R Ball; Kamaljit S Balaggan; Rafael J Yáñez-Muñoz; Robin R Ali; H Bobby Gaspar; Luca Biasco; Alessandro Aiuti; Daniela Cesana; Eugenio Montini; Luigi Naldini; Odile Cohen-Haguenauer; Fulvio Mavilio; Adrian J Thrasher; Hanno Glimm; Christof von Kalle; William Saurin; Manfred Schmidt
Journal:  Nat Med       Date:  2009-11-22       Impact factor: 53.440

10.  Long-term follow-up of foamy viral vector-mediated gene therapy for canine leukocyte adhesion deficiency.

Authors:  Thomas R Bauer; Laura M Tuschong; Katherine R Calvo; Heather R Shive; Tanya H Burkholder; Eleanor K Karlsson; Robert R West; David W Russell; Dennis D Hickstein
Journal:  Mol Ther       Date:  2013-03-26       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.